Projects
Novel, rationally designed combination strategies, based on genomic and proteomic analyses, to enhance the response to cetuximab therapy in head and neck cancer. University of Antwerp
Investigation of non-thermal plasma therapy with first-line treatments of recurrent and metastatic head and neck squamous cell carcinoma: a novel combination with platinum-based chemotherapy and immunotherapy. University of Antwerp
ActoBiotics for antigen-specific intervention in type 1 diabetes: mono- and combination therapy. KU Leuven
KOTK Novel combination therapies to combat therapy resistant neuroblastoma: translating preclinical investigations to clinical trials. KU Leuven
The aims of this project are two-fold: (1) further evaluate the efficacy and toxicity of nutlin, alectinib, palbociclib, silvestrol and TMPYP4 in combination with currently used chemotherapeutic agents in neuroblastoma treatment, including cisplatin, cyclophosphamide, doxorubicin, etoposide, vincristine, topotecan, irinotecan, temozolomide and busulfan using in vitro cell line experiments and xenograft cell line models and (2) to determine ...
Preclinical evaluation of THZ531-Nutlin-3 combination therapy to combat therapy-resistant neuroblastoma Ghent University
Neuroblastoma (NB) is a highly aggressive embryonal malignancy of the sympathetic nervous system. Despite
intensive multi-modal therapy, only half of high-risk patients survive while suffering from severe and long-term
treatment related side effects. While our discovery of ALK activating mutations opened the way to precision
...
Preclinical investigation of immunotherapy and VEGF-targeted therapy in combination with voluntary exercise as novel treatment strategy for malignant pleural mesothelioma. University of Antwerp
Rationally designed drug combination screen in more physiologically relevant in vitro organoid models: can we improve personalised therapy for pancreatic cancer? University of Antwerp
Promising theranostic hybrid systems based on Inorganic Nanoparticles coated with Poly(2-oxazoline)s-conjugates for combination cancer therapy Ghent University
Combination therapies can address the intractability of cancer and provide a better and promising approach for tumor therapy compared to single-mode therapy. The focus of the current project is the development of the chemical approaches to prepare the Doxorubicin-Poly(2-alkyl-2-oxazoline)s conjugates with a cathepsin cleavable valine-alanine dipeptide linker and proper end-group modification to attaching onto Au NPs and (iron oxide ...
Combination of targeted therapy and chemotherapy in acute lymphoblastic leukemia Ghent University
Acute lymphoblastic leukemia (ALL) is an aggressive leukemia that is most common in children and adolescents. Longterm ALL survival rates have significantly improved by the use of intensified chemotherapy and reach 80% in pediatric cases, and 60% in adult ALL, but are associated with substantial acute and long-term side effects. Moreover, the outcome of ALL patients with primary resistant or relapsed disease remains extremely poor en ...